Fig. 6.
Effect of CD31 peptide on GVHD-related mortality and disease severity. B10.D2 bone marrow cells (1.25 × 106) and 5 × 106 spleen cells were transplanted into lethally irradiated (8.0 Gy) BALB/c recipients. Recipient mice received 100 μg/d of CD31 peptide or control peptide 100 μg/d or PBS (IP) for the first 5 weeks after transplantation. (A) Survival curve; (B) mean body weight curve. Date are pooled from 2 similar experiments.
